Home / Companies / Mcneil Sweden
Company family
Mcneil Sweden: medicine shortages
As of 2 Nov 2026, 7 Mcneil Sweden products have a reported shortage across 2 countries, covering 5 medicines.
Products short7rank #251 of 464
Medicines5active ingredients
Countries2/16
New in 90 days6+6 vs market pace
Typical duration21 daysmedian so far
Manufacturing50%demand-driven 25%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
Latest changes
All changesNo changes recorded yet. Changes are tracked from our daily snapshots.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
Download CSV| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Famotidine, Combinations | 2 | 23 Apr 2026 | Quality problem or recall | 1/16 | |
| Sodium Lauryl Sulfoacetate, incl. Combinations | 2 | 12 Oct 2026 | Not stated | 1/16 | |
| Levocabastine | 1 | 18 Sep 2026 | Manufacturing problem | 2/16 | |
| Loperamide | 1 | 2 Nov 2026 | Not stated | 6/16 | |
| Silicones | 1 | 19 Oct 2026 | Increased demand | 3/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.